- TRADE NAME: Keytruda (Merck Sharpe & Dohme)
- INDICATIONS: Unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor
- SYNONYM: Lambrolizumab
- CLASS: Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor), Immune checkpoint inhibitor (incl. programmed death receptor-1 (PD-1) inhibitor), Monoclonal antibody
- HALF-LIFE: 26 days
- FDA APPROVAL DATE: 09/04/2014
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE links (above) to see two reviews of pembrolizumab in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 06/14/2025
